Schleedoorn, MJ
Fleischer, K
Braat, DDM
Oerlemans, AJM
van der Velden, AAEM
Peek, R
Funding for this research was provided by:
Merck B.V. The Netherlands (A16- 1395, A16- 1395, A16- 1395, A16- 1395)
Article History
Received: 17 December 2021
Accepted: 10 August 2022
First Online: 22 September 2022
Declarations
:
: The study protocol for performing OTC and additional genetic testing in young females with TS has been approved by the Central Committee on Research Involving Human Subjects in November 2017 (CCMO NL57738.000.16). Written informed consent was obtained from the patient and her parents.
: Informed consent was obtained from the patient and her parents for the publication of this case report.
: The authors have no conflicts of interest.